Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 200M 175M 161M 149M 282M 19.05B 287M 1.93B 756M 9.38B 750M 734M 32.26B P/E 2026 *
-1.22x
P/E 2027 * -2.02x
Enterprise Value 200M 175M 161M 149M 282M 19.05B 287M 1.93B 756M 9.38B 750M 734M 32.26B EV / Sales 2026 *
5.84x
EV / Sales 2027 * 2.53x
Free-Float
99.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tonix Pharmaceuticals Holding Corp

Manager TitleAgeSince
Chief Executive Officer 68 15/11/2007
Director of Finance/CFO 52 31/01/2016
Chief Tech/Sci/R&D Officer - 02/12/2024
Director TitleAgeSince
Director/Board Member 78 12/02/2018
Director/Board Member 66 08/06/2020
Director/Board Member 81 04/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-3.72%-1.10%+18.41%+70.56% 161B
Average -1.18%-3.25%+26.72%+56.70% 397.1B
Weighted average by Cap. -1.31%-2.96%+36.75%+83.91%

Financials

2026 *2027 *
Net sales 34.18M 29.9M 27.58M 25.47M 48.33M 3.26B 49.15M 330M 129M 1.61B 128M 126M 5.52B 78.93M 69.04M 63.68M 58.82M 112M 7.53B 113M 761M 299M 3.71B 296M 290M 12.75B
Net income -170M -149M -137M -127M -240M -16.21B -244M -1.64B -643M -7.99B -638M -624M -27.45B -152M -133M -122M -113M -215M -14.48B -218M -1.46B -575M -7.13B -570M -558M -24.52B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-